ID

21964

Description

A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3; ODM derived from: https://clinicaltrials.gov/show/NCT00866138

Link

https://clinicaltrials.gov/show/NCT00866138

Keywords

Versions (1)
  1. 5/10/17 5/10/17 -
Uploaded on

May 10, 2017

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Multiple Myeloma NCT00866138

English

Eligibility Multiple Myeloma NCT00866138

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
confirmed multiple myeloma with a t (4; 14) translocation by fish and pcr, expressing or not expressing fgfr3 identified by facs
Description

Multiple Myeloma | t(4;14) Fluorescent in Situ Hybridization | t(4;14) Polymerase Chain Reaction | fibroblast growth factor receptor 3 Fluorescence-Activated Cell Sorting | fibroblast growth factor receptor 3 Expression Fluorescence-Activated Cell Sorting

Data type

boolean

Alias
UMLS CUI [1]
C0026764
UMLS CUI [2,1]
C2986942
UMLS CUI [2,2]
C0162789
UMLS CUI [3,1]
C2986942
UMLS CUI [3,2]
C0032520
UMLS CUI [4,1]
C0117718
UMLS CUI [4,2]
C0079366
UMLS CUI [5,1]
C0117718
UMLS CUI [5,2]
C1171362
UMLS CUI [5,3]
C0079366
patients with multiple myeloma progressing or relapsing after at least two prior therapies (including conventional chemotherapy and/or high dose therapy) or who get a reduction of m-protein less than 75% within 3 months after a high dose treatment (melphalan 200mg/m2) or after the plateau obtained for 3 months duration following to a conventional chemotherapy
Description

Multiple Myeloma Progressing | Multiple Myeloma Relapsing | Therapeutic procedure Quantity | Chemotherapy | high-dose chemotherapy | M Protein Percentage Reduction | Melphalan

Data type

boolean

Alias
UMLS CUI [1,1]
C0026764
UMLS CUI [1,2]
C0205329
UMLS CUI [2,1]
C0026764
UMLS CUI [2,2]
C0035020
UMLS CUI [3,1]
C0087111
UMLS CUI [3,2]
C1265611
UMLS CUI [4]
C0392920
UMLS CUI [5]
C1328050
UMLS CUI [6,1]
C0700271
UMLS CUI [6,2]
C0439165
UMLS CUI [6,3]
C0392756
UMLS CUI [7]
C0025241
life expectancy > 3 months
Description

Life Expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0023671
patient with rapidly progressive disease with cytopenia and / or renal failure have to be stabilized with chemotherapy (if possible 3 cycles of vtd ( bortezomib/thalidomide/dexamethasone) or high dose melphalan regimen followed by a 4 weeks washout period before the inclusion in the study.
Description

Rapidly progressive disorder | Cytopenia | Kidney Failure | Chemotherapy Quantity | bortezomib | Thalidomide | Dexamethasone | Melphalan High dose | Washout Period

Data type

boolean

Alias
UMLS CUI [1]
C1850776
UMLS CUI [2]
C0010828
UMLS CUI [3]
C0035078
UMLS CUI [4,1]
C0392920
UMLS CUI [4,2]
C1265611
UMLS CUI [5]
C1176309
UMLS CUI [6]
C0039736
UMLS CUI [7]
C0011777
UMLS CUI [8,1]
C0025241
UMLS CUI [8,2]
C0444956
UMLS CUI [9]
C1710661
patients must have a clearly detectable and quantifiable monoclonal m- component value (>5 g/l) in the serum and / or urine light chain excretion (>0,5 g/d)
Description

M Protein monoclonal Value Serum | M Protein monoclonal Value Urine light chain measurement

Data type

boolean

Alias
UMLS CUI [1,1]
C0700271
UMLS CUI [1,2]
C0746619
UMLS CUI [1,3]
C1522609
UMLS CUI [1,4]
C0229671
UMLS CUI [2,1]
C0700271
UMLS CUI [2,2]
C0746619
UMLS CUI [2,3]
C1522609
UMLS CUI [2,4]
C1445962
ecog = 0 -2
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior corticosteroids within two weeks before enrolment
Description

Adrenal Cortex Hormones

Data type

boolean

Alias
UMLS CUI [1]
C0001617
prior local irradiation within two weeks before enrolment
Description

Therapeutic radiology procedure Local

Data type

boolean

Alias
UMLS CUI [1,1]
C1522449
UMLS CUI [1,2]
C0205276
prior experimental or standard treatment (other than steroids and local irradiation) within 30 days before enrolment
Description

Therapies, Investigational | Therapeutic procedure | Steroids | Therapeutic radiology procedure Local

Data type

boolean

Alias
UMLS CUI [1]
C0949266
UMLS CUI [2]
C0087111
UMLS CUI [3]
C0038317
UMLS CUI [4,1]
C1522449
UMLS CUI [4,2]
C0205276
contra-indication to high dose steroids (including ongoing active infection)
Description

Medical contraindication Steroids High dose

Data type

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0038317
UMLS CUI [1,3]
C0444956
patient treated for a cancer other than mm within 5 years before enrolment, with the exception of basal cell carcinoma or cervical cancer in situ
Description

Cancer treatment | Multiple Myeloma | Basal cell carcinoma | Carcinoma in situ of uterine cervix

Data type

boolean

Alias
UMLS CUI [1]
C0920425
UMLS CUI [2]
C0026764
UMLS CUI [3]
C0007117
UMLS CUI [4]
C0851140
Back to the top of the page

Similar models

Eligibility Multiple Myeloma NCT00866138

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Multiple Myeloma | t(4;14) Fluorescent in Situ Hybridization | t(4;14) Polymerase Chain Reaction | fibroblast growth factor receptor 3 Fluorescence-Activated Cell Sorting | fibroblast growth factor receptor 3 Expression Fluorescence-Activated Cell Sorting
Item
confirmed multiple myeloma with a t (4; 14) translocation by fish and pcr, expressing or not expressing fgfr3 identified by facs
boolean
C0026764 (UMLS CUI [1])
C2986942 (UMLS CUI [2,1])
C0162789 (UMLS CUI [2,2])
C2986942 (UMLS CUI [3,1])
C0032520 (UMLS CUI [3,2])
C0117718 (UMLS CUI [4,1])
C0079366 (UMLS CUI [4,2])
C0117718 (UMLS CUI [5,1])
C1171362 (UMLS CUI [5,2])
C0079366 (UMLS CUI [5,3])
Multiple Myeloma Progressing | Multiple Myeloma Relapsing | Therapeutic procedure Quantity | Chemotherapy | high-dose chemotherapy | M Protein Percentage Reduction | Melphalan
Item
patients with multiple myeloma progressing or relapsing after at least two prior therapies (including conventional chemotherapy and/or high dose therapy) or who get a reduction of m-protein less than 75% within 3 months after a high dose treatment (melphalan 200mg/m2) or after the plateau obtained for 3 months duration following to a conventional chemotherapy
boolean
C0026764 (UMLS CUI [1,1])
C0205329 (UMLS CUI [1,2])
C0026764 (UMLS CUI [2,1])
C0035020 (UMLS CUI [2,2])
C0087111 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0392920 (UMLS CUI [4])
C1328050 (UMLS CUI [5])
C0700271 (UMLS CUI [6,1])
C0439165 (UMLS CUI [6,2])
C0392756 (UMLS CUI [6,3])
C0025241 (UMLS CUI [7])
Life Expectancy
Item
life expectancy > 3 months
boolean
C0023671 (UMLS CUI [1])
Rapidly progressive disorder | Cytopenia | Kidney Failure | Chemotherapy Quantity | bortezomib | Thalidomide | Dexamethasone | Melphalan High dose | Washout Period
Item
patient with rapidly progressive disease with cytopenia and / or renal failure have to be stabilized with chemotherapy (if possible 3 cycles of vtd ( bortezomib/thalidomide/dexamethasone) or high dose melphalan regimen followed by a 4 weeks washout period before the inclusion in the study.
boolean
C1850776 (UMLS CUI [1])
C0010828 (UMLS CUI [2])
C0035078 (UMLS CUI [3])
C0392920 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
C1176309 (UMLS CUI [5])
C0039736 (UMLS CUI [6])
C0011777 (UMLS CUI [7])
C0025241 (UMLS CUI [8,1])
C0444956 (UMLS CUI [8,2])
C1710661 (UMLS CUI [9])
M Protein monoclonal Value Serum | M Protein monoclonal Value Urine light chain measurement
Item
patients must have a clearly detectable and quantifiable monoclonal m- component value (>5 g/l) in the serum and / or urine light chain excretion (>0,5 g/d)
boolean
C0700271 (UMLS CUI [1,1])
C0746619 (UMLS CUI [1,2])
C1522609 (UMLS CUI [1,3])
C0229671 (UMLS CUI [1,4])
C0700271 (UMLS CUI [2,1])
C0746619 (UMLS CUI [2,2])
C1522609 (UMLS CUI [2,3])
C1445962 (UMLS CUI [2,4])
ECOG performance status
Item
ecog = 0 -2
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Adrenal Cortex Hormones
Item
prior corticosteroids within two weeks before enrolment
boolean
C0001617 (UMLS CUI [1])
Therapeutic radiology procedure Local
Item
prior local irradiation within two weeks before enrolment
boolean
C1522449 (UMLS CUI [1,1])
C0205276 (UMLS CUI [1,2])
Therapies, Investigational | Therapeutic procedure | Steroids | Therapeutic radiology procedure Local
Item
prior experimental or standard treatment (other than steroids and local irradiation) within 30 days before enrolment
boolean
C0949266 (UMLS CUI [1])
C0087111 (UMLS CUI [2])
C0038317 (UMLS CUI [3])
C1522449 (UMLS CUI [4,1])
C0205276 (UMLS CUI [4,2])
Medical contraindication Steroids High dose
Item
contra-indication to high dose steroids (including ongoing active infection)
boolean
C1301624 (UMLS CUI [1,1])
C0038317 (UMLS CUI [1,2])
C0444956 (UMLS CUI [1,3])
Cancer treatment | Multiple Myeloma | Basal cell carcinoma | Carcinoma in situ of uterine cervix
Item
patient treated for a cancer other than mm within 5 years before enrolment, with the exception of basal cell carcinoma or cervical cancer in situ
boolean
C0920425 (UMLS CUI [1])
C0026764 (UMLS CUI [2])
C0007117 (UMLS CUI [3])
C0851140 (UMLS CUI [4])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial